WO1995005454A1 - Bacteriophages mis au point par genie genetique et vaccins les contenant - Google Patents

Bacteriophages mis au point par genie genetique et vaccins les contenant Download PDF

Info

Publication number
WO1995005454A1
WO1995005454A1 PCT/GB1994/001827 GB9401827W WO9505454A1 WO 1995005454 A1 WO1995005454 A1 WO 1995005454A1 GB 9401827 W GB9401827 W GB 9401827W WO 9505454 A1 WO9505454 A1 WO 9505454A1
Authority
WO
WIPO (PCT)
Prior art keywords
bacteriophage
phage
protein
peptide
hybrid
Prior art date
Application number
PCT/GB1994/001827
Other languages
English (en)
Inventor
Fulvia Di Marzo Veronese
Ettore Appella
Anne Elizabeth Willis
Richard Nelson Perham
Original Assignee
Cambridge Bacteriophage Technologies Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939317304A external-priority patent/GB9317304D0/en
Application filed by Cambridge Bacteriophage Technologies Ltd. filed Critical Cambridge Bacteriophage Technologies Ltd.
Publication of WO1995005454A1 publication Critical patent/WO1995005454A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/675—Beta-endorphins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates to engineered bacteriophage and vaccines containing them. Background of the Invention
  • Figure 1 is a schematic view of a hybrid filamentous bacteriophage. It shows a gene III protein 1, a coat protein with epitope 2, a wild-type coat protein 3, and an epitope 4 that is too large for normal packing of subunits.
  • Epitope libraries allow large numbers (sometimes tens of millions) of small peptides to be surveyed for any desirable property, e.g. tight binding to an antibody, receptor or other binding protein.
  • An epitope library can be used to find the antigenic target of the antibodies, hence identifying the physiological site of the disease and suggesting a route for therapeutic procedures. It may also be possible to discover peptides which mimic the biologically-active regions of hormones, cytokines, enzyme substrates, neuropeptides and other bio olecules. Peptides which could either replace or alter the action of the natural ligands would be powerful candidates for drug development.
  • the hybrid hage allows the number of copies of a peptide displayed on each viral particle to be controlled within wide limits, and can confer great sensitivity.
  • hybrid MN phage (2 ⁇ g/well) or hybrid MN phage and wild-type phage fd (20 ⁇ g/well) .
  • the hybrid MN phage is equivalent to 1 ⁇ g peptide/well.
  • the peptides were: 12-mer, IHIGPGRAFYTT; 23- mer, YNKRKRIHIGPGRAFYTTKNIIG.
  • Sequence Type Nucleotide Sequence Length: 18 bases Strandedness: Single Topology: Linear GGGATCGTTA ACCTCAGC

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

On a mis au point par génie génétique un bactériophage filamenteux permettant de faire apparaître des épitopes des lymphocytes T et des épitopes des lymphocytes B et/ou un peptide capable de produire des anticorps neutralisant le VIH. On a pu ainsi observer une immunogénicité efficace.
PCT/GB1994/001827 1992-02-22 1994-08-19 Bacteriophages mis au point par genie genetique et vaccins les contenant WO1995005454A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95832192A 1992-02-22 1992-02-22
GB9317304.5 1993-08-19
GB939317304A GB9317304D0 (en) 1993-08-19 1993-08-19 Engineered bacteriophages and their use

Publications (1)

Publication Number Publication Date
WO1995005454A1 true WO1995005454A1 (fr) 1995-02-23

Family

ID=26303401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1994/001827 WO1995005454A1 (fr) 1992-02-22 1994-08-19 Bacteriophages mis au point par genie genetique et vaccins les contenant

Country Status (1)

Country Link
WO (1) WO1995005454A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1088889A1 (fr) * 1999-10-01 2001-04-04 University Of Cambridge Bactériophage filamenteux double-hybride recombinant
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
EP1729799A2 (fr) * 2004-01-09 2006-12-13 Kary B. Mullis Immunite programmable chimiquement
US7232564B2 (en) 2001-07-18 2007-06-19 Instytut Immunologii I Terapii Doswiadczal-Nej Pan Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections
WO2010036132A1 (fr) 2008-09-29 2010-04-01 Instytut Immunologii i Terapii Doświadczalnej PAN Nouvelles souches de bactériophage pour le traitement d’infections bactériennes, en particulier des souches pharmacorésistantes du genre enterococcus
US7850975B2 (en) 1999-12-22 2010-12-14 Altermune Technologies, Llc Chemically programmable immunity
WO2011162626A1 (fr) 2010-06-20 2011-12-29 Instytut Immunologii i Terapii Doświadczalnej PAN Nouvelles souches de bactériophages pour le traitement d'infections bactériennes, en particulier par des souches de bactéries pharmacorésistantes du genre stenotrophomonas
US8604184B2 (en) 2009-05-05 2013-12-10 The United States Of America As Represented By The Secretary Of The Air Force Chemically programmable immunity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429816A1 (fr) * 1989-10-31 1991-06-05 F. Hoffmann-La Roche Ag Composition de vaccin à base d'un épitope non-immunosuppressif de cellules T
WO1992007077A1 (fr) * 1990-10-12 1992-04-30 Cambridge Bacteriophage Technologies Limited Bacteriophages modifies par genie genetique et vaccins les contenant
GB2253626A (en) * 1991-01-24 1992-09-16 British Tech Group Antigen-presenting chimaeric protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429816A1 (fr) * 1989-10-31 1991-06-05 F. Hoffmann-La Roche Ag Composition de vaccin à base d'un épitope non-immunosuppressif de cellules T
WO1992007077A1 (fr) * 1990-10-12 1992-04-30 Cambridge Bacteriophage Technologies Limited Bacteriophages modifies par genie genetique et vaccins les contenant
GB2253626A (en) * 1991-01-24 1992-09-16 British Tech Group Antigen-presenting chimaeric protein

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANNE E. WILLIS ET AL: "Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage", GENE, vol. 128, 1993 *
DANI P. BOLOGNESI: "HIV antibodies and vaccine design", AIDS, vol. 3, no. 1, 1989 *
Dialog Information Service, file 154, Medline, Dialog accession No. 06508754, Medline accession No. 88153754, de la Cruz VF et al: "Immunogenicity and *epitope* mapping of foreign sequences via genetically engineered filamentous phage", J Biol Chem (UNITED STATES) Mar 25 1988, 263 (9) p 4318-22 *
National Library of Medicine (NLM), file Medline, Medline accession no. 93212503, Keller PM: "Identification of HIV vaccine candidate peptides by screening random phage epitope libraries", Virology 1993 Apr; 193(2):709-16 *
O.O. MINENKOVA ET AL: "Design of specific immunogens using filamentous phage as the carrier", GENE, vol. 128, 1993, XP023539031, DOI: doi:10.1016/0378-1119(93)90157-X *
R.L. WARREN ET AL: "Method for identifying microbial antigens that stimulate specific lymphocyte responses: Application to Salmonella", PROC. NATL. ACAD. SCI, vol. 87, 1990, USA *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025416A1 (fr) * 1999-10-01 2001-04-12 University Of Cambridge Bacteriophage filamenteux double-hybride recombinant
EP1088889A1 (fr) * 1999-10-01 2001-04-04 University Of Cambridge Bactériophage filamenteux double-hybride recombinant
US8236321B2 (en) 1999-12-22 2012-08-07 Altermune Technologies, Llc Chemically programmable immunity
US8591910B2 (en) 1999-12-22 2013-11-26 Altermune Technologies Llc Chemically programmable immunity
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
US8263082B2 (en) 1999-12-22 2012-09-11 Altermune Technologies Llc Chemically programmable immunity
US7850975B2 (en) 1999-12-22 2010-12-14 Altermune Technologies, Llc Chemically programmable immunity
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7232564B2 (en) 2001-07-18 2007-06-19 Instytut Immunologii I Terapii Doswiadczal-Nej Pan Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections
EP1729799A2 (fr) * 2004-01-09 2006-12-13 Kary B. Mullis Immunite programmable chimiquement
EP1729799A4 (fr) * 2004-01-09 2008-11-05 Kary B Mullis Immunite programmable chimiquement
WO2010036132A1 (fr) 2008-09-29 2010-04-01 Instytut Immunologii i Terapii Doświadczalnej PAN Nouvelles souches de bactériophage pour le traitement d’infections bactériennes, en particulier des souches pharmacorésistantes du genre enterococcus
US8604184B2 (en) 2009-05-05 2013-12-10 The United States Of America As Represented By The Secretary Of The Air Force Chemically programmable immunity
WO2011162626A1 (fr) 2010-06-20 2011-12-29 Instytut Immunologii i Terapii Doświadczalnej PAN Nouvelles souches de bactériophages pour le traitement d'infections bactériennes, en particulier par des souches de bactéries pharmacorésistantes du genre stenotrophomonas

Similar Documents

Publication Publication Date Title
EP0552267B1 (fr) Bacteriophages modifies par genie genetique et vaccins les contenant
EP0572433B1 (fr) Capside presentant un antigene, avec une proteine enveloppe de ms2 de fusion
JP3851938B2 (ja) 植物、動物、およびヒトのワクチンとして並びに免疫療法に有用な抗体の免疫優性エピトープの弱化
Keller et al. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries
CA2170412C (fr) Virus de vegetaux modifies utilise, en tant que vecteurs de peptides heterologues
RU2201421C2 (ru) Синтетический пептид hiv (варианты), иммуногенная композиция для индукции иммунного ответа против пептидов hiv, диагностический набор для определения hiv-специфичных антител
Nardelli et al. A chemically defined synthetic vaccine model for HIV-1.
HRP970092A2 (en) Synthetic hiv genes
EP1098910A1 (fr) Complexe antigenique comprenant un peptide immunostimulateur, cd4 et un domaine de recepteur de chemokine pour traiter vih et des maladies immunitaires
EP0787139B1 (fr) Peptides de synthese et vaccins les contenant
CA2084180A1 (fr) Expression d'immunogenes specifiques a l'aide d'antigenes viraux
JP2006020635A (ja) 抗原的に標識した非感染性レトロウィルス様粒子
JPH04502760A (ja) エイズの診断，予防および治療に有効な新規ｈｉｖ蛋白質およびペプチド
WO1994018234A1 (fr) Obtention de proteines de recombinaison contenant des determinants antigeniques multiples lies par des domaines d'articulation souples
WO1995005454A1 (fr) Bacteriophages mis au point par genie genetique et vaccins les contenant
EP0651806B1 (fr) Vaccins contre le virus de l'immunodeficience anti-feline (vif)
EP0728015B1 (fr) Procede de preparation d'un set d' antigenes polypeptidiques combinatoires
EP0322394A2 (fr) Expression des protéines de HIV dans E.coli et S.cerevisiae
JPS63254983A (ja) エイズの病原であるウイルスのｐ２５蛋白質をコードするウイルスベクター及び組換ＤＮＡ、感染された細胞培養物、得られる蛋白質、ワクチン及び得られる抗体
US20060275309A1 (en) Peptide oligomers for use as hiv vaccines
Boudet et al. Fine analysis of immunoreactivity of V3 peptides: antibodies specific for V3 domain of laboratory HIV type 1 strains recognize multiple V3 sequences synthesized from field HIV type 1 isolates
PH26855A (en) Vaccines against acquired immune deficiency syndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 604958

Date of ref document: 19960603

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase